JP7082130B2 - Ｔｙｋ２阻害剤およびその使用 - Google Patents
Ｔｙｋ２阻害剤およびその使用 Download PDFInfo
- Publication number
- JP7082130B2 JP7082130B2 JP2019541679A JP2019541679A JP7082130B2 JP 7082130 B2 JP7082130 B2 JP 7082130B2 JP 2019541679 A JP2019541679 A JP 2019541679A JP 2019541679 A JP2019541679 A JP 2019541679A JP 7082130 B2 JP7082130 B2 JP 7082130B2
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- sulfur
- oxygen
- disorder
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000195A JP7498200B2 (ja) | 2016-10-14 | 2022-01-04 | Ｔｙｋ２阻害剤およびその使用 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408464P | 2016-10-14 | 2016-10-14 | |
| US62/408,464 | 2016-10-14 | ||
| US201662410327P | 2016-10-19 | 2016-10-19 | |
| US201662410334P | 2016-10-19 | 2016-10-19 | |
| US62/410,334 | 2016-10-19 | ||
| US62/410,327 | 2016-10-19 | ||
| US201662413829P | 2016-10-27 | 2016-10-27 | |
| US62/413,829 | 2016-10-27 | ||
| US201662415920P | 2016-11-01 | 2016-11-01 | |
| US62/415,920 | 2016-11-01 | ||
| US201762468767P | 2017-03-08 | 2017-03-08 | |
| US201762468807P | 2017-03-08 | 2017-03-08 | |
| US201762468749P | 2017-03-08 | 2017-03-08 | |
| US62/468,807 | 2017-03-08 | ||
| US62/468,749 | 2017-03-08 | ||
| US62/468,767 | 2017-03-08 | ||
| US201762546278P | 2017-08-16 | 2017-08-16 | |
| US62/546,278 | 2017-08-16 | ||
| PCT/US2017/056555 WO2018071794A1 (en) | 2016-10-14 | 2017-10-13 | Tyk2 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000195A Division JP7498200B2 (ja) | 2016-10-14 | 2022-01-04 | Ｔｙｋ２阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535807A JP2019535807A (ja) | 2019-12-12 |
| JP2019535807A5 JP2019535807A5 (https=) | 2020-11-19 |
| JP7082130B2 true JP7082130B2 (ja) | 2022-06-07 |
Family
ID=61906011
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541679A Active JP7082130B2 (ja) | 2016-10-14 | 2017-10-13 | Ｔｙｋ２阻害剤およびその使用 |
| JP2022000195A Active JP7498200B2 (ja) | 2016-10-14 | 2022-01-04 | Ｔｙｋ２阻害剤およびその使用 |
| JP2023091142A Withdrawn JP2023106606A (ja) | 2016-10-14 | 2023-06-01 | Ｔｙｋ２阻害剤およびその使用 |
| JP2025202716A Pending JP2026035684A (ja) | 2016-10-14 | 2025-11-25 | Ｔｙｋ２阻害剤およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000195A Active JP7498200B2 (ja) | 2016-10-14 | 2022-01-04 | Ｔｙｋ２阻害剤およびその使用 |
| JP2023091142A Withdrawn JP2023106606A (ja) | 2016-10-14 | 2023-06-01 | Ｔｙｋ２阻害剤およびその使用 |
| JP2025202716A Pending JP2026035684A (ja) | 2016-10-14 | 2025-11-25 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10323036B2 (https=) |
| EP (2) | EP3848370B1 (https=) |
| JP (4) | JP7082130B2 (https=) |
| CN (1) | CN109952303B (https=) |
| AU (3) | AU2017342464B2 (https=) |
| CA (1) | CA3039202A1 (https=) |
| ES (1) | ES2930198T3 (https=) |
| IL (2) | IL265922B2 (https=) |
| TW (2) | TWI763722B (https=) |
| WO (1) | WO2018071794A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3262049B1 (en) | 2015-02-27 | 2022-07-20 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| EP3848370B1 (en) | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| EP3528816A4 (en) * | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| GB201617871D0 (en) * | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| JP7160824B2 (ja) | 2017-03-08 | 2022-10-25 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| KR102717819B1 (ko) | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| AU2019234574A1 (en) | 2018-03-12 | 2020-09-03 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| JP7530360B2 (ja) * | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| CN120865208A (zh) | 2019-01-23 | 2025-10-31 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| WO2020159904A1 (en) * | 2019-01-30 | 2020-08-06 | Bristol-Myers Squibb Company | Amide-disubstituted pyridine or pyridazine compounds |
| WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| WO2021009568A1 (en) | 2019-07-17 | 2021-01-21 | 2692372 Ontario, Inc. | Benzenesulfonamide derivatives and uses thereof |
| WO2021048736A1 (en) * | 2019-09-11 | 2021-03-18 | Pfizer Inc. | Treatment of hidradenitis with jak inhibitors |
| CN115003667B (zh) | 2020-02-26 | 2025-04-15 | 百济神州有限公司 | Tyk-2抑制剂 |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| WO2021237121A1 (en) * | 2020-05-21 | 2021-11-25 | Gossamer Bio Services, Inc. | Substituted pyridines |
| IL299294A (en) * | 2020-06-22 | 2023-02-01 | Beigene Ltd | tyk-2 inhibitor |
| WO2022083560A1 (zh) * | 2020-10-19 | 2022-04-28 | 南京药石科技股份有限公司 | Tyk2选择性抑制剂及其用途 |
| GB2617477A (en) | 2020-11-20 | 2023-10-11 | 2692372 Ontario Inc | Benzenesulfonamide derivatives and uses thereof |
| WO2022136914A1 (en) * | 2020-12-23 | 2022-06-30 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| CA3207819A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| IL305165A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| US12600721B2 (en) | 2021-02-19 | 2026-04-14 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| AU2022268464B2 (en) * | 2021-05-04 | 2025-04-17 | Shanghai Zheye Biotechnology Co. Ltd. | Nitrogen-containing heterocyclic pyridine compound |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| WO2023055901A2 (en) | 2021-09-30 | 2023-04-06 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| WO2023116822A1 (en) * | 2021-12-23 | 2023-06-29 | Beigene, Ltd. | Solid forms of a tyk2 inhibitor, method of preparation, and use thereof |
| WO2023220046A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Tyk2 inhibitors |
| WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
| US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| CN115819429A (zh) * | 2022-12-13 | 2023-03-21 | 成都睿智化学研究有限公司 | 一种5-氯-2,3-二氢呋喃[2,3-c]吡啶的合成方法 |
| WO2024193689A1 (zh) * | 2023-03-23 | 2024-09-26 | 广东东阳光药业股份有限公司 | 吡啶并吡咯衍生物及其在药物中的用途 |
| WO2024211708A1 (en) * | 2023-04-06 | 2024-10-10 | Myrobalan Therapeutics, Inc. | Tyk2 inhibitors for treatment of glaucoma |
| WO2024217523A1 (en) * | 2023-04-20 | 2024-10-24 | Myrobalan Therapeutics Nanjing Co. Ltd | Selective tky2 inhibitors and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085267A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 含窒素縮合環誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2015069310A1 (en) | 2013-11-07 | 2015-05-14 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB599891A (en) * | 1944-11-17 | 1948-03-23 | Gen Aniline & Film Corp | 1-substituted-2,5-diketo-7-methyl-pyrimido-pyrazoles and process of preparing the same |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| US20050043315A1 (en) * | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CA2637172A1 (en) * | 2006-01-27 | 2007-08-09 | Array Biopharma Inc. | Pyridin-2-amine derivatives and their use as glucokinase activators |
| JP2009525978A (ja) * | 2006-02-06 | 2009-07-16 | アイアールエム・リミテッド・ライアビリティ・カンパニー | プロテインキナーゼ阻害剤としての化合物および組成物 |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| US8846704B2 (en) * | 2007-01-31 | 2014-09-30 | YM Biosciences Austraila Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| EA200901133A1 (ru) * | 2007-03-20 | 2010-04-30 | Смитклайн Бичем Корпорейшн | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| WO2009155156A1 (en) | 2008-06-18 | 2009-12-23 | Merck & Co., Inc. | Inhibitors of janus kinases |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| AU2011272862A1 (en) * | 2010-06-30 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
| AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| US9033542B2 (en) * | 2010-11-16 | 2015-05-19 | Dialight Corporation | LED luminaire utilizing an extended and non-metallic enclosure |
| MX2013005445A (es) * | 2010-11-19 | 2013-07-29 | Hoffmann La Roche | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). |
| EP2802576B1 (en) * | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106614A1 (en) * | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104254533B (zh) * | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| US9315494B2 (en) | 2012-11-08 | 2016-04-19 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| AU2014211856C1 (en) * | 2013-02-02 | 2018-04-12 | Centaurus Biopharma Co., Ltd. | Substituted 2-aminopyridine protein kinase inhibitor |
| WO2014210354A1 (en) * | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| WO2015073267A1 (en) * | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2015131080A1 (en) * | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| NO2721710T3 (https=) * | 2014-08-21 | 2018-03-31 | ||
| EP3262049B1 (en) | 2015-02-27 | 2022-07-20 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TW201718571A (zh) * | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| EP3848370B1 (en) | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
-
2017
- 2017-10-13 EP EP21157963.6A patent/EP3848370B1/en active Active
- 2017-10-13 TW TW106135165A patent/TWI763722B/zh active
- 2017-10-13 US US15/783,250 patent/US10323036B2/en active Active
- 2017-10-13 IL IL265922A patent/IL265922B2/en unknown
- 2017-10-13 CN CN201780069795.3A patent/CN109952303B/zh active Active
- 2017-10-13 IL IL315777A patent/IL315777A/en unknown
- 2017-10-13 AU AU2017342464A patent/AU2017342464B2/en active Active
- 2017-10-13 EP EP17860009.4A patent/EP3526222B1/en active Active
- 2017-10-13 CA CA3039202A patent/CA3039202A1/en active Pending
- 2017-10-13 ES ES17860009T patent/ES2930198T3/es active Active
- 2017-10-13 TW TW111113673A patent/TWI825663B/zh active
- 2017-10-13 JP JP2019541679A patent/JP7082130B2/ja active Active
- 2017-10-13 WO PCT/US2017/056555 patent/WO2018071794A1/en not_active Ceased
-
2019
- 2019-04-30 US US16/399,296 patent/US10793574B2/en active Active
-
2020
- 2020-05-04 US US16/865,924 patent/US11220508B2/en active Active
-
2021
- 2021-09-03 AU AU2021225251A patent/AU2021225251A1/en not_active Abandoned
- 2021-09-17 US US17/448,013 patent/US20220073527A1/en not_active Abandoned
-
2022
- 2022-01-04 JP JP2022000195A patent/JP7498200B2/ja active Active
-
2023
- 2023-06-01 JP JP2023091142A patent/JP2023106606A/ja not_active Withdrawn
- 2023-09-26 AU AU2023237060A patent/AU2023237060B2/en active Active
-
2025
- 2025-11-25 JP JP2025202716A patent/JP2026035684A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085267A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 含窒素縮合環誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2015069310A1 (en) | 2013-11-07 | 2015-05-14 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Non-Patent Citations (7)
| Title |
|---|
| Gazzetta Chimica Italiana，1957年，Vol.87，p.931-948 |
| J Prakt Chem，1998年，Vol.340，p.408-423 |
| Journal of Heterocyclic Chemistry，2005年，Vol.42, No.6，p.1181-1183 |
| Phosphorus, Sulfur and Silicon，2001年，Vol.176，p.49-59 |
| Polish Journal of Chemistry，1979年，Vol.53, No.12，p.2491-2499 |
| PubChem CID 824807，URL=https://pubchem.ncbi.nlm.nih.gov/compound/824807 |
| Tetrahedron，2016年，Vol.72，p.5754-5761 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7498200B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| JP6802263B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| JP7530360B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| JP6526065B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| EP3262049B1 (en) | Tyk2 inhibitors and uses thereof | |
| JP2023546996A (ja) | Ｃｔｐｓ１阻害剤およびその使用 | |
| JP2022518505A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| CN115448916B (zh) | Tyk2抑制剂及其用途 | |
| HK40055822B (en) | Tyk2 inhibitors and uses thereof | |
| HK40055822A (en) | Tyk2 inhibitors and uses thereof | |
| HK40009936B (en) | Tyk2 inhibitors and uses thereof | |
| HK40009936A (en) | Tyk2 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201008 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201008 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220104 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220516 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220526 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7082130 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |